There are 2867 resources available
1121P - Real-world (RW) data from the sotorasib French pre-market authorization early access program in patients (pts) with KRASG12C driven metastatic non-small cell lung cancer (mNSCLC): Clinical characteristics
Presenter: Jacques Cadranel
Session: Poster session 15
849P - Time from primary melanoma to first distant recurrence in relation to survival outcomes in metastatic melanoma
Presenter: Isabella van Duin
Session: Poster session 03
1654P - Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)
Presenter: Mimi Hu
Session: Poster session 11
1122P - An adjusted comparison of amivantamab phase II data versus real-world clinical management in France of EGFR exon 20 insertion-mutated (ex20ins) advanced NSCLC patients
Presenter: Christos Chouaid
Session: Poster session 15
850P - A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
Presenter: Amelia Taylor
Session: Poster session 03
1655P - Dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer
Presenter: Young-kyung Jeon
Session: Poster session 11
1123P - Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study
Presenter: Jianying Zhou
Session: Poster session 15
851P - Frequency and clinical significance of homologous recombination deficiency gene mutations in non-cutaneous melanoma
Presenter: Yue Yang
Session: Poster session 03
1656P - Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): Update of the LIBRETTO-001 trial
Presenter: Matthias Kroiss
Session: Poster session 11
1124P - Pralsetinib in RET fusion-positive non-small cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)
Presenter: Antonio Passaro
Session: Poster session 15